Journal article
Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase ii pivotal trial
S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, W Jurczak, SP Mulligan, A Schuh, S Assouline, CM Wendtner, AW Roberts, MS Davids, J Bloehdorn, T Munir, S Böttcher, L Zhou, AH Salem, M Desai, B Chyla Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2018
Abstract
Purpose Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia [del(17p) CLL] was based on results from 107 patients. An additional 51 patients were enrolled in a safety expansion cohort. Extended analysis of all enrolled patients, including the effect of minimal residual disease (MRD) negativity on outcome, is now reported. Patients and Methods Overall, 158 patients with relapsed/refractory or previously untreated (n = 5) del(17p) CLL received venetoclax 400 mg per day after an initial dose ramp up. Responses were based on 2008 Inte..
View full abstractGrants
Funding Acknowledgements
Funded by AbbVie and Genentech. Venetoclax is being developed in collaboration between AbbVie and Genentech. AbbVie and Genentech provided financial support for the study and participated in the design, study conduct, analysis, and interpretation of data, as well as the writing, review, and approval of the manuscript.